Literature DB >> 19396468

Fatal pulmonary fibrosis after rituximab administration.

Marie-Camille Chaumais1, Arnaud Garnier, François Chalard, Michel Peuchmaur, Stephane Dauger, Evelyne Jacqz-Agrain, Georges Deschênes.   

Abstract

Idiopathic nephrotic syndrome is the most frequent glomerular disease during childhood. Although immunosuppressive agents are usually effective, some severe cases remain difficult to treat. We describe a female patient with secondary steroid-resistant nephrotic syndrome who no longer responded to conventional treatment. Owing to cyclosporine toxicity, rituximab was administered. Three days after treatment the patient's clinical condition dramatically worsened and she developed acute respiratory distress. Despite all means used to treat her, she died 5 weeks after rituximab infusion. A pulmonary biopsy showed extensive fibrosis, while the alveolar epithelium was no longer visible.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19396468     DOI: 10.1007/s00467-009-1195-9

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  14 in total

1.  Interstitial pneumonitis related to rituximab therapy.

Authors:  Catherine Burton; Richard Kaczmarski; Riaz Jan-Mohamed
Journal:  N Engl J Med       Date:  2003-06-26       Impact factor: 91.245

2.  Rituximab-induced acute pulmonary fibrosis.

Authors:  Rafael J Leon; Americo Gonsalvo; Rafael Salas; Nelly C Hidalgo
Journal:  Mayo Clin Proc       Date:  2004-07       Impact factor: 7.616

3.  Resolution of recurrent focal segmental glomerulosclerosis proteinuria after rituximab treatment.

Authors:  Mark D Pescovitz; Benita K Book; Richard A Sidner
Journal:  N Engl J Med       Date:  2006-05-04       Impact factor: 91.245

4.  Rituximab in patients with the steroid-resistant nephrotic syndrome.

Authors:  Arvind Bagga; Aditi Sinha; Asha Moudgil
Journal:  N Engl J Med       Date:  2007-06-28       Impact factor: 91.245

5.  Fatal interstitial pneumonitis related to rituximab-containing regimen.

Authors:  Yair Herishanu; Aaron Polliack; Leonor Leider-Trejo; Yoel Grieff; Ur Metser; Elizabeth Naparstek
Journal:  Clin Lymphoma Myeloma       Date:  2006-03

6.  Fatal intra-alveolar hemorrhage after rituximab in a patient with non-Hodgkin lymphoma.

Authors:  Doru T Alexandrescu; Janice P Dutcher; Kevin O'Boyle; Mehmet Albulak; Stanley Oiseth; Peter H Wiernik
Journal:  Leuk Lymphoma       Date:  2004-11

7.  Change of the course of steroid-dependent nephrotic syndrome after rituximab therapy.

Authors:  Kerstin Benz; Jörg Dötsch; Wolfgang Rascher; Daniel Stachel
Journal:  Pediatr Nephrol       Date:  2004-04-08       Impact factor: 3.714

Review 8.  Rituximab-induced interstitial lung disease.

Authors:  Stephanie A Wagner; Apurva C Mehta; Damian A Laber
Journal:  Am J Hematol       Date:  2007-10       Impact factor: 10.047

9.  Remission of steroid-resistant nephrotic syndrome due to focal and segmental glomerulosclerosis using rituximab.

Authors:  Megha Suri; Kim Tran; Ajay P Sharma; Guido Filler; Joanne Grimmer
Journal:  Int Urol Nephrol       Date:  2008-05-20       Impact factor: 2.370

10.  Acute respiratory distress syndrome after rituximab infusion.

Authors:  Alberto J Montero; John J McCarthy; George Chen; Lawrence Rice
Journal:  Int J Hematol       Date:  2005-11       Impact factor: 2.490

View more
  47 in total

Review 1.  Rituximab therapy for refractory steroid-resistant nephrotic syndrome in children.

Authors:  Koichi Kamei; Kenji Ishikura; Mayumi Sako; Shuichi Ito; Kandai Nozu; Kazumoto Iijima
Journal:  Pediatr Nephrol       Date:  2018-12-18       Impact factor: 3.714

Review 2.  New therapies, new concerns: rituximab-associated lung injury.

Authors:  Larry C Lands
Journal:  Pediatr Nephrol       Date:  2010-03-02       Impact factor: 3.714

3.  Severe respiratory adverse events associated with rituximab infusion.

Authors:  Koichi Kamei; Shuichi Ito; Kazumoto Iijima
Journal:  Pediatr Nephrol       Date:  2009-12-19       Impact factor: 3.714

Review 4.  New therapies in steroid-sensitive and steroid-resistant idiopathic nephrotic syndrome.

Authors:  Michael van Husen; Markus J Kemper
Journal:  Pediatr Nephrol       Date:  2011-01-13       Impact factor: 3.714

5.  Short-term effects of rituximab in children with steroid- and calcineurin-dependent nephrotic syndrome: a randomized controlled trial.

Authors:  Pietro Ravani; Alberto Magnasco; Alberto Edefonti; Luisa Murer; Rossella Rossi; Luciana Ghio; Elisa Benetti; Floriana Scozzola; Andrea Pasini; Nadia Dallera; Felice Sica; Mirco Belingheri; Francesco Scolari; Gian Marco Ghiggeri
Journal:  Clin J Am Soc Nephrol       Date:  2011-05-12       Impact factor: 8.237

6.  Infusion reactions associated with rituximab treatment for childhood-onset complicated nephrotic syndrome.

Authors:  Koichi Kamei; Masao Ogura; Mai Sato; Shuichi Ito; Kenji Ishikura
Journal:  Pediatr Nephrol       Date:  2018-02-09       Impact factor: 3.714

Review 7.  Rituximab and minimal change nephrotic syndrome: a therapeutic option.

Authors:  Takashi Takei; Kosaku Nitta
Journal:  Clin Exp Nephrol       Date:  2011-05-26       Impact factor: 2.801

Review 8.  Treatment of steroid-sensitive nephrotic syndrome: new guidelines from KDIGO.

Authors:  Rebecca M Lombel; Debbie S Gipson; Elisabeth M Hodson
Journal:  Pediatr Nephrol       Date:  2012-10-03       Impact factor: 3.714

9.  Fulminant viral myocarditis after rituximab therapy in pediatric nephrotic syndrome.

Authors:  Anne-Laure Sellier-Leclerc; Emre Belli; Valérie Guérin; Peter Dorfmüller; Georges Deschênes
Journal:  Pediatr Nephrol       Date:  2013-05-23       Impact factor: 3.714

Review 10.  Rituximab therapy in nephrotic syndrome: implications for patients' management.

Authors:  Aditi Sinha; Arvind Bagga
Journal:  Nat Rev Nephrol       Date:  2013-01-22       Impact factor: 28.314

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.